In the long struggle between human ingenuity and cancer's capacity for evasion, researchers at City of Hope in Los Angeles have opened a new front: immune cells that can be reprogrammed after they are already inside the body. Where current CAR T therapies are fixed at the moment of infusion—unable to respond when tumors mutate and hide—the meCAR T platform introduces adaptability as a core feature of treatment. Like a living software system, it invites the possibility that medicine need not anticipate every threat in advance, but can instead learn and respond alongside the disease.
City of Hope Develops 'Plug-and-Play' CAR T Technology to Combat Tumor Evolution
Instead of hardwiring every function, add new capabilities as needed.
Mark
So the core problem here is that CAR T cells can't adapt once they're in the patient. Why is that such a big deal?
Mimi
Because tumors are constantly evolving. They develop new mutations, new ways to hide from the immune system. A CAR T cell that was perfectly programmed to recognize cancer in the lab might become useless six months later when the tumor has changed.
Mark
And the new meCAR T system fixes that by letting doctors reprogram the cells after infusion?
Mimi
Exactly. Instead of trying to anticipate every possible threat before you put the cells in, you can add new instructions later—like sending a software update to a phone that's already in someone's pocket.
Luke
But this is preclinical work, right? They've shown it works in the lab. Has it been tested in actual patients yet?
Mimi
Not yet. That's what the Phase I trials are for. They're just starting those now, so we won't know for months or years whether this actually improves outcomes in people.
Mark
What cancers are they testing it on first?
Mimi
Solid tumors and acute myeloid leukemia. Solid tumors are the harder problem—they're more heterogeneous, meaning the cancer cells vary a lot even within the same tumor.
Luke
And we should note that City of Hope is the organization doing this research and running the trials. They have an obvious interest in showing it works. That doesn't mean it won't, but it's worth keeping in mind.
Mark
Fair point. What's the timeline looking like?
Mimi
Phase I trials typically take a couple of years. If those go well, you'd move to Phase II to test effectiveness more rigorously. So we're probably looking at several years before we know whether this actually helps patients live longer or have better outcomes.
Mark
But if it does work, the implications are pretty broad?
Mimi
Potentially, yes. The researchers think the meditope platform could apply to many different cancers and other diseases where CAR T therapy is being developed. It's a platform, not a one-off fix.
Il Polso
- Tumors have long exploited a fatal flaw in CAR T therapy: once infused, the reprogrammed immune cells are locked into their original instructions, leaving patients vulnerable to relapse when cancer evolves new defenses.
- City of Hope researchers John Williams and Christine Brown engineered a molecular docking system—meditope—that allows scientists to push new capabilities to CAR T cells already circulating inside a patient, turning a static tool into an updatable one.
- Preclinical results showed meCAR T cells could be equipped with add-ons that improved tumor tracking, cell growth, and recognition of cancer variants—a critical advantage against solid tumors, where no two cancer cells are quite alike.
- City of Hope is now launching Phase I clinical trials targeting solid tumors and acute myeloid leukemia, the first real-world test of whether laboratory adaptability survives contact with the complexity of actual patients.
- If the trials succeed, the meditope platform could extend across many cancers where CAR T therapies are under development, reframing immunotherapy not as a fixed prescription but as an evolving, responsive treatment.
In the long struggle between human ingenuity and cancer's capacity for evasion, researchers at City of Hope in Los Angeles have opened a new front: immune cells that can be reprogrammed after they are already inside the body. Where current CAR T therapies are fixed at the moment of infusion—unable to respond when tumors mutate and hide—the meCAR T platform introduces adaptability as a core feature of treatment. Like a living software system, it invites the possibility that medicine need not anticipate every threat in advance, but can instead learn and respond alongside the disease.
At City of Hope in Los Angeles, researchers have engineered a way to update cancer-fighting immune cells after they are already inside a patient's body—a development that could fundamentally change how immunotherapy responds to tumors that refuse to stay still.
CAR T cell therapy has transformed treatment for blood cancers by reprogramming a patient's own immune cells to hunt down cancer. But it carries a critical limitation: once infused, those cells are locked into their original programming. When tumors mutate and find new ways to hide, the therapy cannot follow. Patients relapse.
John Williams and Christine Brown set out to solve that problem by building on a molecular system called meditope—a kind of docking port that allows new instructions to be attached to immune cells after deployment. The result, meCAR T, works like a smartphone software update: rather than hardwiring every function before treatment begins, researchers can push new capabilities to cells already in the body—helping them track tumors more effectively, multiply when needed, or recognize cancer cells that have evolved new disguises. The work was published this month in Cancer Immunology Research.
The flexibility matters most for solid tumors, where cancer cells vary widely even within the same tumor. Brown noted that instead of trying to anticipate every possible threat before infusion, the platform allows researchers to respond to what actually unfolds inside the patient.
City of Hope is now launching two Phase I trials to test meCAR T safety and effectiveness in solid tumors and acute myeloid leukemia. The institution—which already runs one of the nation's largest cellular therapy programs—has long positioned itself as a bridge between discovery and clinical use. The meCAR T platform embodies that philosophy: a tool designed not just to work in theory, but to change how oncologists respond when cancer fights back.
In Los Angeles, researchers at City of Hope have engineered a way to update cancer-fighting cells after they're already inside a patient's body—a shift that could reshape how immunotherapy adapts to tumors that refuse to stay still.
CAR T cell therapy works by taking a patient's own immune cells, rewriting their genetic instructions in the lab, and sending them back into the bloodstream to hunt down and destroy cancer. It has transformed treatment for blood cancers. But the approach has a critical flaw: once those reprogrammed cells are infused, they're locked into their original programming. If a tumor mutates and finds new ways to hide, the CAR T cells can't follow. The cancer adapts. The therapy doesn't. Patients relapse.
John Williams, director of City of Hope's X-ray Crystallography Core, and Christine Brown, deputy director of T Cell Therapeutics Research Laboratories, set out to solve that problem. They built on Williams's earlier work with a molecular system called meditope—essentially a docking port that lets scientists attach new instructions to immune cells after they've been deployed. The team redesigned CAR T cells to accept these molecular add-ons, creating what they call meCAR T cells. The innovation was published this month in Cancer Immunology Research, a journal of the American Association for Cancer Research.
The breakthrough is straightforward in concept but significant in scope. Think of it like a smartphone software update: instead of hardwiring every function into the device before you leave the store, you can push new features to it later, as needs change. With meCAR T, researchers can equip cells with new capabilities after infusion—helping them track tumors more effectively, multiply when needed, or recognize cancer cells that have evolved new disguises. The cells become adaptive rather than static.
In their preclinical work, Williams and Brown demonstrated that meCAR T cells could be outfitted with different molecular add-ons that enhanced tracking, growth, and the ability to recognize a broader range of cancer types. The flexibility matters most for solid tumors, where cancer cells are notoriously heterogeneous—meaning they vary widely even within the same tumor, making them harder to target with a one-size-fits-all therapy. Brown noted that instead of trying to anticipate every possible threat before infusion, the platform allows researchers to respond to what actually happens in the patient's body.
The next phase is clinical. City of Hope is launching two Phase I trials to test whether meCAR T cells are safe and effective in patients with solid tumors and acute myeloid leukemia. These early-stage studies will determine whether the promise of the lab translates to real patients. If successful, the approach could extend beyond these cancers; researchers believe the meditope platform could eventually apply to many diseases where CAR T therapies are being developed.
City of Hope already operates one of the nation's largest cellular therapy programs, treating roughly 90 percent of its CAR T patients in outpatient settings and enrolling more than 2,000 patients in immune cell trials over time. The institution has positioned itself as a bridge between discovery and clinical use, moving innovations from the bench into patient care relatively quickly. The meCAR T platform represents that philosophy: a tool designed not just to work in theory, but to change how oncologists actually treat cancer when tumors fight back.
Citazioni salienti
Tumors adapt to CAR T therapies, leading to treatment failure and cancer relapse. To remain effective, our therapies need to adapt, too.— John Williams, director of City of Hope's X-ray Crystallography Core
Much like a software update adds new features to a smartphone after you buy it, meditope allows us to send new instructions to CAR T cells already in the body.— John Williams
Vuoi la storia completa?
Leggi l'originale su Mirage News ↗
Health & Medicine